PACS earnings analysis
What we found in PACS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PACS delivered strong Q2 growth, with revenue up 9.1% year over year to $1.428 billion, operating income up 35.8%, and diluted EPS up to $0.47 from $0.31. Performance was underpinned by 5.8% same-store skilled-nursing revenue growth and a 150-basis-point occupancy gain, while six-month operating cash flow rose to $371.8 million. The principal offsets are a sequential operating-margin/EPS decline, substantial acquisition cash deployment, ongoing DOJ/SEC matters, and unremediated material weaknesses in financial-reporting controls.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth beat consensus
- Q2 revenue rose $118.8 million, or 9.1% year over year, to $1.428 billion. This was also $6.9 million above the $1.421 billion consensus estimate supplied with the filing metadata.
- Year-over-year margin expansion
- Operating income increased $28.8 million, or 35.8%, to $109.3 million, lifting operating margin to 7.7% from 6.1% a year ago. Gross margin expanded to 23.7% from 22.0%, although it declined from 24.4% in Q1 2026.
- EPS increased 52% year over year
- Diluted EPS was $0.47, up $0.16 from $0.31 a year ago; adjusted EPS rose to $0.63 from $0.47. GAAP EPS declined $0.03 from Q1 2026's $0.50.
- Same-store occupancy and mix improved
- Same-store skilled nursing revenue grew $74.0 million, or 5.8%, while same-store occupancy improved 150 basis points to 90.6%. Same-store skilled mix by patient days increased 50 basis points to 29.7%.
- Operating cash flow accelerated
- Six-month operating cash flow increased $169.0 million to $371.8 million. Days sales outstanding improved by 5.0 days to 46.9 days, supporting working-capital conversion.
- Credit line repaid and buyback authorized
- The company had $164.5 million of cash and no borrowings on its credit facility after $45.0 million of net line repayments in Q2. It also authorized $250.0 million for repurchases, all of which remained available at June 30.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses remain unremediated
- Management concluded disclosure controls were not effective as of June 30, 2026 because material weaknesses remain in the control environment and revenue processes. The weaknesses previously resulted in restatements of the March 31, 2024 and June 30, 2024 interim financial statements.
- Regulatory and SEC investigations continue
- Four DOJ matters and an SEC Enforcement investigation remain ongoing. The company cannot estimate a loss or range of loss; legal and other costs were $8.2 million in Q2 and $19.9 million in the first six months of 2026.
- Insurance and financing costs increased
- Cost pressure persists: facility liability insurance expense increased $26.2 million year over year in Q2, while interest expense increased $1.7 million to $6.0 million. Inflation-driven reimbursement adjustments may not match future labor, supply, and capital-cost inflation.
- Acquisition spending consumed cash
- Cash declined $55.1 million in the first six months to $176.9 million including restricted cash, as investing outflows reached $282.7 million. Real-estate acquisition spending was $190.8 million and property/equipment capex was $48.4 million.
- No formal risk-factor update; California concentrated
- No material changes were reported to the risk factors in the February 27, 2026 10-K. However, California represents 140 of 324 facilities and 16,132 of 35,631 beds/units, creating material geographic concentration.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.47
- Gross margin
- 23.7%
- Operating margin
- 7.7%
- Segment
- Skilled nursing services revenue: $1.376 billion, up $98.1 million (7.7%) year over year.
- Segment
- Assisted living, independent living and supplemental revenue: increased $20.5 million year over year; five facilities were added since June 30, 2025.
What they said about what is next.
The 10-Q provides no explicit quantitative revenue, EPS, or EBITDA outlook. Management states that current cash balances and operating cash flow are expected to cover operating needs for at least the next 12 months.
The filing reads better than the one before it.
What came before.
- 10-Q · May 11, 2026
- PACS Group, Inc. reported strong revenue growth of 11.2%, reaching $1.42 billion, and a significant increase in diluted EPS to $0.45, a 184.2% rise compared to the same period last year. Operating income surged by…
- 10-K · February 27, 2026
- PACS Group, Inc. has shown significant growth and improvement in financial performance, driven primarily by their robust acquisition strategy in the post-acute healthcare sector. Revenue for the year ended December 31,…
- 10-Q · November 19, 2025
- PACS Group, Inc. reported strong financial results for Q3 2025, with significant revenue growth driven by an increase in patient days and operational facilities. The company demonstrated healthy margins but experienced…
- 10-Q · November 19, 2025
- PACS Group reported strong revenue growth but fell short of EPS expectations in Q3 2025. Total revenue surged to $1.34B, a 30% increase year-over-year, driven by significant patient care increases, but diluted EPS came…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PACS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever